1832 Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

1832 Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-729	Closed	-$20K	–	773
2019 Q3	$20K	Hold	729	–	–	﹤0.01%	607
2019 Q2	$20K	Hold	729	–	–	﹤0.01%	615
2019 Q1	$25K	Hold	729	–	–	﹤0.01%	541
2018 Q4	$14K	Hold	729	–	–	﹤0.01%	544
2018 Q3	$19K	Hold	729	–	–	﹤0.01%	576
2018 Q2	$29K	Buy	+729	New	+$27.9K	﹤0.01%	539

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

1832 Asset Management's PTLA Position: Q4 2019 in Review

1832 Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2019, closing a stake of 729 shares — an estimated $20K sold.

1832 Asset Management first reported a position in PTLA in Q2 2018 and held it in 6 quarters. The position peaked at $29K in Q2 2018. 224 funds tracked by Wall St. Rank hold PTLA as of Q4 2019.

1832 Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
1832 Asset Management sold 729 Portola Pharmaceuticals, Inc. shares in Q4 2019, an estimated $20K.
1832 Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2018 and held it in 6 quarters.
1832 Asset Management's Portola Pharmaceuticals, Inc. position peaked at $29K in Q2 2018.
224 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2019.

Based on 1832 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.